Effects on atrial fibrillation in aged hypertensive rats by Ca 2+-activated K+ channel inhibition

Hypertension

Volumn 57, Issue 6, 2011, Pages 1129-1135

  Diness, Jonas G ^a,b   Skibsbye, Lasse ^a   Jespersen, Thomas ^b   Bartels, Emil D ^c   Sørensen, Ulrik S ^a   Hansen, Rie S ^d   Grunnet, Morten ^a,b  

^a NEUROSEARCH A S   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Rigshospitalet   (Denmark)

^d Zealand Pharma AS   (Denmark)

Author keywords

antiarrhythmia agents; atrial fibrillation; ion channels; NS8593; spontaneously hypertensive rats; UCL1684

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM ACTIVATED POTASSIUM CHANNEL; NS 8593; UCL 1684; UNCLASSIFIED DRUG;

AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART PACING; HYPERTENSION; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 85027940247     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.170613     Document Type: Article

References (29)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946-952. (Pubitemid 28446646)
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983-988.
3. Li D, Sun H, Levesque P. Antiarrhythmic drug therapy for atrial fibrillation: focus on atrial selectivity and safety. Cardiovasc Hematol Agents Med Chem. 2009;7:64-75.
4. Xu Y, Tuteja D, Zhang Z, Xu D, Zhang Y, Rodriguez J, Nie L, Tuxson HR, Young JN, Glatter KA, Vazquez AE, Yamoah EN, Chiamvimonvat N. Molecular identification and functional roles of a Ca(2-)-activated K channel in human and mouse hearts. J Biol Chem. 2003;278: 49085-49094.
5. Tuteja D, Xu D, Timofeyev V, Lu L, Sharma D, Zhang Z, Xu Y, Nie L, Vazquez AE, Young JN, Glatter KA, Chiamvimonvat N. Differential expression of small-conductance Ca2-activated K channels SK1, SK2, and SK3 in mouse atrial and ventricular myocytes. Am J Physiol Heart Circ Physiol. 2005;289:H2714-H2723. (Pubitemid 41698589)
6. Lu L, Zhang Q, Timofeyev V, Zhang Z, Young JN, Shin HS, Knowlton AA, Chiamvimonvat N. Molecular coupling of a Ca2-activated K channel to L-type Ca2 channels via-actinin2. Circ Res. 2007;100:112-120. (Pubitemid 46066779)
7. Ozgen N, Dun W, Sosunov EA, Anyukhovsky EP, Hirose M, Duffy HS, Boyden PA, Rosen MR. Early electrical remodeling in rabbit pulmonary vein results from trafficking of intracellular SK2 channels to membrane sites. Cardiovasc Res. 2007;75:758-769. (Pubitemid 47238736)
8. Li N, Timofeyev V, Tuteja D, Xu D, Lu L, Zhang Q, Zhang Z, Singapuri A, Albert TR, Rajagopal AV, Bond CT, Periasamy M, Adelman J, Chiamvimonvat N. Ablation of a Ca2-activated K channel (SK2 channel) results in action potential prolongation in atrial myocytes and atrial fibrillation. J Physiol. 2009;587:1087-1100.
9. Diness JG, Sorensen US, Nissen JD, Al-Shahib B, Jespersen T, Grunnet M, Hansen RS. Inhibition of small-conductance Ca2-activated K channels terminates and protects against atrial fibrillation. Circ Arrhythm Electrophysiol. 2010;3:380-390.
10. Marionneau C, Couette B, Liu J, Li H, Mangoni ME, Nargeot J, Lei M, Escande D, Demolombe S. Specific pattern of ionic channel gene expression associated with pacemaker activity in the mouse heart. J Physiol. 2005;562:223-234. (Pubitemid 40207799)
11. Zhang Q, Timofeyev V, Lu L, Li N, Singapuri A, Long MK, Bond CT, Adelman JP, Chiamvimonvat N. Functional roles of a Ca2-activated K channel in atrioventricular nodes. Circ Res. 2008;102:465-471. (Pubitemid 351651104)
12. Lu L, Timofeyev V, Li N, Rafizadeh S, Singapuri A, Harris TR, Chiamvimonvat N.-actinin2 cytoskeletal protein is required for the functional membrane localization of a Ca2-activated K channel (SK2 channel). Proc Natl Acad Sci USA. 2009;106:18402-18407.
13. Ellinor PT, Lunetta KL, Glazer NL, Pfeufer A, Alonso A, Chung MK, Sinner MF, de Bakker PI, Mueller M, Lubitz SA, Fox E, Darbar D, Smith NL, Smith JD, Schnabel RB, Soliman EZ, Rice KM, Van Wagoner DR, Beckmann BM, van NC, Wang K, Ehret GB, Rotter JI, Hazen SL, Steinbeck G, Smith AV, Launer LJ, Harris TB, Makino S, Nelis M, Milan DJ, Perz S, Esko T, Kottgen A, Moebus S, Newton-Cheh C, Li M, Mohlenkamp S, Wang TJ, Kao WH, Vasan RS, Nothen MM, MacRae CA, Stricker BH, Hofman A, Uitterlinden AG, Levy D, Boerwinkle E, Metspalu A, Topol EJ, Chakravarti A, Gudnason V, Psaty BM, Roden DM, Meitinger T, Wichmann HE, Witteman JC, Barnard J, Arking DE, Benjamin EJ, Heckbert SR, Kaab S. Common variants in KCNN3 are associated with lone atrial fibrillation. Nat Genet. 2010;42:240-244.
14. Allessie MA, Boyden PA, Camm AJ, Kleber AG, Lab MJ, Legato MJ, Rosen MR, Schwartz PJ, Spooner PM, Van Wagoner DR, Waldo AL. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001; 103:769-777. (Pubitemid 32144209)
15. Chugh SS, Blackshear JL, Shen WK, Hammill SC, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371-378.
16. Levy S. Factors predisposing to the development of atrial fibrillation. Pacing Clin Electrophysiol. 1997;20:2670-2674.
17. Bing OH, Brooks WW, Robinson KG, Slawsky MT, Hayes JA, Litwin SE, Sen S, Conrad CH. The spontaneously hypertensive rat as a model of the transition from compensated left ventricular hypertrophy to failure. J Mol Cell Cardiol. 1995;27:383-396.
18. Conrad CH, Brooks WW, Hayes JA, Sen S, Robinson KG, Bing OH. Myocardial fibrosis and stiffness with hypertrophy and heart failure in the spontaneously hypertensive rat. Circulation. 1995;91:161-170.
19. Cerbai E, Barbieri M, Li Q, Mugelli A. Ionic basis of action potential prolongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages. Cardiovasc Res. 1994;28:1180-1187. (Pubitemid 24264724)
20. Dunn FG, Pfeffer MA, Frohlich ED. ECG alterations with progressive left ventricular hypertrophy in spontaneous hypertension. Clin Exp Hypertens. 1978;1:67-86. (Pubitemid 9038843)
21. Guinamard R, Demion M, Magaud C, Potreau D, Bois P. Functional expression of the TRPM4 cationic current in ventricular cardiomyocytes from spontaneously hypertensive rats. Hypertension. 2006;48:587-594. (Pubitemid 44843860)
22. Noresson E, Ricksten SE, Thoren P. Left atrial pressure in normotensive and spontaneously hypertensive rats. Acta Physiol Scand. 1979;107:9-12. (Pubitemid 10193741)
23. Heaton DA, Lei M, Li D, Golding S, Dawson TA, Mohan RM, Paterson DJ. Remodeling of the cardiac pacemaker L-type calcium current and its-adrenergic responsiveness in hypertension after neuronal NO synthase gene transfer. Hypertension. 2006;48:443-452. (Pubitemid 44253739)
24. Choisy SC, Arberry LA, Hancox JC, James AF. Increased susceptibility to atrial tachyarrhythmia in spontaneously hypertensive rat hearts. Hypertension. 2007;49:498-505.
25. de Bakker JM, van Capelle FJ, Janse MJ, Tasseron S, Vermeulen JT, de JN, Lahpor JR. Slow conduction in the infarcted human heart: 'zigzag' course of activation. Circulation. 1993;88:915-926. (Pubitemid 23264006)
26. Moe GK, Abildskov JA. Atrial fibrillation as a self-sustaining arrhythmia independent of focal discharge. Am Heart J. 1959;58:59-70.
27. Nattel S. New ideas about atrial fibrillation 50 years on. Nature. 2002; 415:219-226. (Pubitemid 34059528)
28. Haissaguerre M, Jais P, Shah DC, Takahashi A, Hocini M, Quiniou G, Garrigue S, Le MA, Le MP, Clementy J. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339:659-666. (Pubitemid 28402090)
29. Strobaek D, Hougaard C, Johansen TH, Sorensen US, Nielsen EO, Nielsen KS, Taylor RD, Pedarzani P, Christophersen P. Inhibitory gating modulation of small conductance Ca2-activated K channels by the synthetic compound (R)-N-(benzimidazol-2-yl)-1,2,3,4-tetrahydro-1-naphtylamine (NS8593) reduces afterhyperpolarizing current in hippocampal CA1 neurons. Mol Pharmacol. 2006;70:1771-1782.